• About
  • Privacy & Policy
  • Contact Us
Procurement Nation
  • Home
  • Suppliers
  • Procurement
    • Shipping
    • Best Procurement Software
    • Supply Chain
      • What is supply chain management?
      • Tyson Foods Food Supply Chain
  • Markets
  • Banking
  • Contact Us
No Result
View All Result
  • Home
  • Suppliers
  • Procurement
    • Shipping
    • Best Procurement Software
    • Supply Chain
      • What is supply chain management?
      • Tyson Foods Food Supply Chain
  • Markets
  • Banking
  • Contact Us
No Result
View All Result
Procurement Nation
No Result
View All Result

US STOCKS-Futures little changed amid lingering Omicron worries

Mark White by Mark White
December 23, 2021
in Supply Chain
0


(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)

* Futures: Dow up 0.10%, S&P flat, Nasdaq off 0.07%

Dec 22 (Reuters) – U.S. stock index futures struggled for direction on Wednesday, cooling off after a day-earlier rally, as worries lingered about the new Omicron variant of the coronavirus and its impact on global economic recovery.

Wall Street’s main indexes ended with hefty gains on Tuesday, but few market-moving catalysts and thin volumes in the last two weeks of trading this year are seen aiding higher volatility. The S&P 500 index is up roughly 24% in 2021.

Investors looked for updates on the Omicron variant after Germany, Scotland, Ireland, Portugal, the Netherlands and South Korea re-imposed lockdowns or other curbs.

Most big technology stocks fell in premarket trading. Apple Inc, Amazon.com Inc, Meta Platforms and Alphabet Inc dropped between 0.1% and 0.4%.

Tesla Inc gained 2.7%, bucking a trend among its megacap peers. According to an interview released on Tuesday, Tesla CEO Elon Musk said he had sold “enough stock” to reach his plan to sell 10% of his shares in company.

At 6:54 a.m. ET, Dow e-minis were up 34 points, or 0.1%, S&P 500 e-minis were up 1.5 points, or 0.03%, and Nasdaq 100 e-minis were down 10.5 points, or 0.07%.

Pfizer rose 0.4% after saying it will provide an additional 2.5 million doses of its COVID-19 pill Paxlovid to the United Kingdom.

Additionally, the U.S. Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer and Merck as early as Wednesday, Bloomberg News reported. Merck climbed around 1.1%.

Markets also awaited a meeting later in the day, where President Joe Biden along with U.S. officials and private sector companies, including FedEx, will talk about ongoing efforts to address supply chain disruptions.

A final reading of gross domestic product data is due at 8:30 a.m. EST, which is expected to have risen 2.1% in the third quarter, unchanged from the previous estimate.

Separately, data from the Conference Board will likely show consumer confidence edged up to 110.8 in December from 109.5 in November. (Reporting by Shreyashi Sanyal and Anisha Sircar in Bengaluru; editing by Uttaresh.V)



Source link

Previous Post

Intel apologises in China over Xinjiang supplier statement

Next Post

China to roll out policies to help exporters amid economic headwinds

Mark White

Mark White

Mark White is the editor of the ProcurementNation, a Media Outlet covering supply chain and logistics issues. He joined The New York Times in 2007 as an commodities reporter, and most recently served as foreign-exchange editor in New York.

Next Post
China to roll out policies to help exporters amid economic headwinds

China to roll out policies to help exporters amid economic headwinds

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • Privacy & Policy
  • Contact Us
Call us: +1 234 JEG THEME

© 2021 Procurement Nation - Supply Chain & Logistics News

No Result
View All Result
  • Procurement
  • Supply Chain
  • Logistics
  • Science
  • Technology

© 2021 Procurement Nation - Supply Chain & Logistics News